SEC Form 4 · accession 0000899243-18-005464
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kathryn E Falberg
Director
Period of report
Feb 26, 2018
Accepted (ET)
Feb 26, 2018 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF2 | Feb 26, 2018 | P | 30,000 | $32.00 | A | 124,894 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reporting Person purchased 30,000 shares of Issuer's common stock in connection with a public offering at the offering price of $32.00 per share.
- F2A portion of these shares is subject to a right of repurchase held by the Issuer.